Comprehensive Phase 1b HER-Vaxx Cancer Vaccine Results Presented at the European Society of Medical Oncology (ESMO) Congress
SYDNEY, Australia, 1 October 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anti- cancer vaccine were presented at the European Society of Medical Oncology in Barcelona, Spain held from 27 September to 1 October 2019.
For further information please download the attached PDF:
Download this document
